MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$3,604K
Net Income
-$128,840K
Net Profit Margin
-3574.92%
EPS
-$0.68
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
3,604
-
0*
-
Cost of goods sold
93
-
-
-
Research and development
97,019
103,846
111,885*
101,950
General and administration
-
33,511
34,938*
35,484
Selling, general and administrative
36,283
-
-
-
Total operating expenses
-
137,357
146,822*
137,434
Intangible asset amortization
750
-
-
-
Gain from divestiture of small molecule programs
-
-
0*
0
Total operating expenses
134,145
-
-
-
Loss from operations
-130,541
-137,357
-146,822*
-137,434
Interest and other income, net
2,988
8,910
10,840*
10,532
Loss before income taxes
-
-
-135,982*
-
Income tax expense
-
-
26*
-
Net loss
-127,553
-128,447
-136,008*
-126,902
Net unrealized gain on marketable securities, net of tax
-1,287
-1,364
66*
162
Comprehensive loss
-128,840
-129,811
-135,942
-126,740
Basic EPS
-0.68
-0.69
-0.781
-0.74
Diluted EPS
-0.68
-0.69
-0.781
-0.74
Basic Average Shares
187,314,501
186,636,978
174,075,952
172,421,492
Diluted Average Shares
187,314,501
186,636,978
174,075,952
172,421,492
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$128,840K
(-2.89%↓ Y/Y)
Net loss
-$127,553K
(-2.77%↓ Y/Y)
Net unrealized gain
on marketable...
-$1,287K
(-17.21%↓ Y/Y)
Interest and other
income, net
$2,988K
(-72.45%↓ Y/Y)
Loss from operations
-$130,541K
(3.28%↑ Y/Y)
Total revenue
$3,604K
Total operating
expenses
$134,145K
(-0.61%↓ Y/Y)
Research and development
$97,019K
(-5.53%↓ Y/Y)
Selling, general and
administrative
$36,283K
Intangible asset
amortization
$750K
Cost of goods sold
$93K
Buy us a coffee
Denali Therapeutics Inc. (DNLI)
Denali Therapeutics Inc. (DNLI)